3 results
Approved WMOCompleted
To validate 18F-Flutemetamol PET in the evaluation of plaque vulnerability.
Approved WMOCompleted
To investigate trastuzmab-paclitaxel in EGFR-mutated NSCLC patients who have overexpression of HER2 and who have progressed on standard TKI-treatment
Approved WMOCompleted
Primary Objectives:- To estimate complete response rate, per pathology review committee (PRC), and its duration in CIS participantsSecondary Objectives:- To evaluate progression free survival, per pathologie review committee (PRC), for all…